Tech Company Financing Transactions
TearClear Funding Round
TearClear, based in Boston, secured $22 million in funding from Bluestem Capital, Flying L Partners and Visionary Venture Fund.
Transaction Overview
Company Name
Announced On
8/13/2020
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series B
Proceeds Purpose
The company intends to use the funds to advance multiple clinical programs in development, with two lead candidates in glaucoma paving the way for future indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Undisclosed
Boston, MA 02101
USA
Boston, MA 02101
USA
Phone
Website
Email Address
Not Recorded
Overview
TearClear is an emerging ophthalmic pharmaceutical company with the goal of disrupting the way current topical medications are delivered to the ocular surface. Our lead product candidates in glaucoma will pave the way for future indications across multiple programs in development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Dempsey
Chief Scientific Officer
Srini Venkatesh
Browse more venture capital transactions:
Prev: 8/13/2020: F2G venture capital transaction
Next: 8/13/2020: mPulse Mobile venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs